Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2024-12-12 Board/Management Inform…
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo Pharmaceuticals appoints Chief Strategy Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Strategy Officer, Dominika Spilarova, effective January 10, 2025. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A). The document structure and content confirm it is a management announcement.
2024-12-12 English
Cosmo Pharmaceuticals ernennt Chief Strategy Officer
Board/Management Information Classification · 100% confidence The document is a press release dated December 12, 2024, announcing the appointment of a new Chief Strategy Officer, Dominika Spilarova, effective January 10, 2025. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, the appropriate classification is MANG.
2024-12-12 German
Cosmo shareholders approved Board proposal to appoint new independent auditor at today’s EGM
AGM Information Classification · 99% confidence The document is a press release dated October 18, 2024, announcing that shareholders approved the appointment of Deloitte Accountants B.V. as the new independent auditor at an Extraordinary General Meeting (EGM). This action relates directly to the company's audit and governance structure. While it mentions an EGM, the core subject is the auditor appointment, which is a key component of the annual audit process and corporate governance. It is not the full Audit Report (AR) itself, nor is it a standard Annual Report (10-K). It is an announcement regarding a governance/audit decision made at a meeting. Given the options, this is most closely related to Governance Information (CGR) or potentially an announcement related to the Audit Report process. Since it specifically details the appointment of the auditor following a shareholder vote at an EGM, it fits well under Governance Information (CGR) as it concerns the structure and oversight of financial reporting. It is too specific for a general Regulatory Filing (RNS) and does not fit the other categories like ER, IR, or DEF 14A. The document is short and acts as an announcement, but the subject matter is substantive governance information.
2024-10-18 English
Cosmo-Aktionäre genehmigen an heutiger a.o. GV den Vorschlag des Verwaltungsrates zur Ernennung eines neuen unabhängigen Auditors
AGM Information Classification · 99% confidence The document is a press release written in German announcing that shareholders approved the appointment of a new independent auditor (Deloitte Accountants B.V.) during an extraordinary General Meeting (a.o. GV). This action relates directly to corporate governance and the oversight of financial reporting integrity. While it concerns an audit appointment, the primary event described is the shareholder vote and the outcome regarding the auditor selection, which is a key component of corporate governance structure. The closest fit among the provided codes is 'Governance Information' (CGR), as the appointment/rotation of auditors is a fundamental governance matter. It is not the Audit Report itself (AR), nor is it a general Annual Report (10-K). It is a specific announcement about a governance decision made at a shareholder meeting, which aligns well with CGR, although AGM-R is also relevant due to the meeting context. Given the focus on the auditor appointment and governance practice (rotation), CGR is the most precise fit over AGM-R, which usually covers the entire meeting agenda/results.
2024-10-18 German
Cosmo Pharmaceuticals appoints new Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is titled 'Ad hoc announcement' and explicitly announces the appointment of a new Chief Financial Officer (CFO) and the transition of the outgoing CFO to a new role focusing on Corporate Governance & Chief Sustainability Officer. This type of announcement details changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' Although the outgoing CFO moves to a role touching on ESG, the primary purpose of this specific release is the executive change, making MANG the most appropriate classification.
2024-10-11 English
Cosmo Pharmaceuticals ernennt neue Finanzchefin
Board/Management Information Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and announces the appointment of a new Chief Financial Officer (CFO) and a change in role for the outgoing CFO, focusing on Corporate Governance & Chief Sustainability Officer. This content directly relates to changes in senior management and board composition. This aligns perfectly with the definition for Board/Management Information (MANG). Although it mentions ESG, the primary focus is the executive personnel change, not a standalone ESG report (SR). It is not a full financial report (10-K, IR) or an earnings release (ER).
2024-10-11 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.